Equol, Adiponectin, Insulin Levels and Risk of Breast Cancer

  • Minatoya, Machiko (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Kutomi, Goro (Department of Surgery I, Sapporo Medical University School of Medicine) ;
  • Asakura, Sumiyo (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Otokozawa, Seiko (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Sugiyama, Yukiko (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Nagata, Yoshie (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Mori, Mitsuru (Department of Public Health, Sapporo Medical University School of Medicine) ;
  • Hirata, Koichi (Department of Surgery I, Sapporo Medical University School of Medicine)
  • Published : 2013.04.30


Breast cancer is one of the most frequently diagnosed cancers and the leading cause of cancer death among women. Soy isoflavones have been widely studied and among all isoflavones equol has been gaining interest with regard to its relationship with breast cancer risk. Obesity has been revealed as one of the breast cancer risk factors, known to be associated with high levels of circulating insulin and decreased levels of adiponectin. Hence there have been many studies investigating relationships between insulin and adiponectin levels and breast cancer risk. Additionally recent findings have suggested that insulin and adiponectin themselves may have influence on breast cancer development, independent of obesity. In the present review, we discuss the relationships between breast cancer risk and equol, insulin and adiponectin levels, which are three important factors in our ongoing hospital-based case-control study. Herein these factors are reviewed not only from the clinical viewpoint but also from possible chemical and biological points of view which may explain clinical observations.



  1. Ahn J, Schatzkin A, Lacey JV Jr, et al (2007). Adiposity, adult weight change, and posymenopausal breast cancer risk. Arch Intern Med, 167, 2091-102.
  2. Akaza H, Miyanaga N, Takashima N, et al (2002). Is daidzein non-metabolizer a high risk for prostate cancer? A casecontrolled study of serum soybean isoflavone concentration. Jpn J Clin Oncol, 32, 296-300,
  3. Al Awadhi SA, Al Khaldi RM, AL Rammah T, Kapila K, Mojiminiyi OA (2012). Associations of adipokines and insulin resistance with sex steroids in patients with breast cancer. Indian J Med Res, 135, 500-5.
  4. Arai Y, Uehara M, Sato Y, et al (2000). Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol, 10, 127-35.
  5. Arditi JD, Venihaki M, Karalis KP, Chrous GP (2007), Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal like between obesity and cancer. Horm Metab Res, 39, 9-13.
  6. Arita Y, Kihara S, Ouchi N, et al (1999). Paradoxical decrease of an adipose specific protein, adiponectin in obesity. Biochem Biophys Res Commun, 257, 79-83.
  7. Arora A, Nair MG, Strasburg GM (1998). Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys, 356, 133-41.
  8. Belfiore A, Costantino A, Frasca F, et al (1996). Overexpression of membrane glycoprotein PC-1 in MDA-MB-231 breast cancer cells in associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol, 10, 1318-26.
  9. Brackenheim E, Veitonmaki N, Cao R, et al (2004). Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101, 2476-81.
  10. Bruning PF, Bonfrer JM, Van Noord PA, et al (1992). Insulin resistance and breast cancer risk. Int J Cancer, 52, 511-6.
  11. Calle EE, Kaaks R (2004). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4, 579-91.
  12. Chappell J, Leitner JW, Solomon S, et al (2001). Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem, 276, 38023-8.
  13. Chen DA, Chung YF, Yeh YT, et al (2006). Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett, 237, 109-14.
  14. Del Giudice ME, Fantus IG, Ezzat S, et al (1998). Insulin and related factors in premenopausal cancer risk. Breast Cancer Res Treat, 47, 111-20.
  15. Dieudonne MN, Bussiere M, Dos Santos E, et al (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 345, 271-9.
  16. Diez JJ, Iglesias P (2003). The role of the novel adipocytederived hormone adiponectin in human disease. Eur J Endocrinol, 148, 293-300.
  17. Dong JY, Qin LQ (2011). Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat, 125, 315-23.
  18. Drazin B (2011). Mechanism of the mitogenic influence of hyperinsulinemia. Diabetology, Metabolic Syndrome, 13, 10.
  19. Gallagher EJ, LeRoith (2010). The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metab, 21, 610-8.
  20. Gliozzo B, Sung CK, Scala P, et al (1998). Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells in mediated by a phosphatidylinositol-3-kinase-independent pathway. J Cellular Biochem, 70, 268-80.<268::AID-JCB12>3.0.CO;2-J
  21. Goodman MT, Shvetsov YB, Wilkens LR, et al (2009). Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethic cohort study. Cancer Prev Res, 2, 887-94.
  22. Grace PB, Taylor JI, Low YL, et al (2004). Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomark Prev, 3, 698-708.
  23. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8.
  24. Gunter MJ, Hoover DR, Yu H, et al (2009). Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 101, 48-60.
  25. Heinonen MS, Hoikkala A, Wahala K, Adlercreutz H (2003). Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Bio, 87, 285-99.
  26. Hutchins AM, Slavin JL, Lampe JW (1995). Urinary isoflavonoid phytoestrogen and lignin excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc, 95, 545-51.
  27. Ingram D, Sanders K, Kolybaba M, Lopez D (1997). Casecontrol study of phyto-oestrogens and breast cancer. Lancet, 350, 990-4.
  28. Ish-Shalom D, Christoffersen CT, Vorwerk P, et al (1997). Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia, 40, 25-31.
  29. Jackson LR, Greiwe JS, Schwen RJ (2011). Emerging evidence of the health benefits of S-equol, an estrogen receptor ${\beta}$ agonist. Nutrition Reviews, 69, 432-48.
  30. Jarde T, Caldefie-Chezet F, Damez M, et al (2008). Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology, 53, 484-7.
  31. Jernstrom H, Barrett-Connor E (1999). Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the rancho bernardo study. J Wom Health Gend Bas Med, 8, 1265-72.
  32. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG (2006). Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogendependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis, 27, 856-63.
  33. Ju YH, Fultz J, Allred KF, et al (2006). Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer, 55, 1-12.
  34. Kaaks R (1996). Nutrition, hormons, and breast cancer: is insulin the missing link? Cancer Causes Control, 7, 605-25.
  35. Kaaks R, Lundin E, Manjer J, et al (2002). Prospective study of IGF-1, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes and Control, 13, 307-16.
  36. Kabat GC, Kim M, Caan BJ, et al (2009). Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer, 125, 2704-10.
  37. Kang JH, Lee YY, Yu BY, et al (2005). Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res, 28, 1263-9.
  38. Kang JH, Yu BY, Youn DS, (2007). Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci, 22, 117-21.
  39. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA (1995). The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med, 208, 40-3.
  40. Kinjo J, Tsuchihashi R, Morito K, et al (2004). Interactions of phytoestrogens with estrogen receptors alpha and beta (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biol Pharm Bull, 27, 185-8.
  41. Korner A, Pazaitou-Panayioyou K, Kelesidis I, et al (2007). Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab, 92, 1041-8.
  42. Kumor A, Daniel P, Pietruczuk M, et al (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patient. Int J Colorectal Dis, 24, 275-8.
  43. Lahmann PH, Hoffmann K, Allen N, et al (2004). Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer, 111, 762-71.
  44. Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998). Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med, 217, 335-9.
  45. Lampe JW (2010). Emerging research on equol and cancer. J Nutr, 140, 1369S-72S.
  46. Li CI, Malone KE, Daling JR (2006). Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control, 17, 695-703.
  47. Lorincz AM, Sukumar S (2006). Molecular links between obesity and breast cancer. Endocr Relat Cancer, 13, 279-92.
  48. Maeda K, Okubo K, Shimomura I, et al (1996). cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun, 221, 286-9.
  49. Magee PJ, Raschke M, Steiner C, et al (2006) Equol: acomparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr Cancer, 54, 232-42.
  50. Malaguarnera R, Sacco A, Voci C, et al (2012). Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinol, 153, 2152-63.
  51. Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89, 1102-7.
  52. Martin PM, Horwithz KB, Ryan DS, McGuire WL, (1987). Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinol, 103, 1860-7.
  53. Martin M, Haourigui M, Pelissero C, et al (1996). Interactions between phytoestrogens and human sex steroid binding protein. Life Sci, 58, 429-36.
  54. Matsuzawa Y, Funahashi T, Nakamura T (1999). Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte derived bioactive substances. Ann NY Acad Sci, 892, 146-54.
  55. Merlo GR, Basolo F, Fiore L, Duboc L, Hynes NE (1995). p53-dependent and p-53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Bio, 128, 1185-96.
  56. Messina M (2010). A brief historical overview of the past two decades of soy and isoflavone research. J Nutr, 140, 1350-4.
  57. Milazzo G, Giorgino F, Damante G, et al (1992). Insulin receptor expression and function in human breast cancer cell lines. Cancer Res, 52, 3924-30.
  58. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002). Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol, 156, 349-68.
  59. Miyoshi Y, Funahashi T, Kihara S, et al (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res, 9, 5699-704.
  60. Muthyala RS, Ju YH, Sheng S, et al (2004). Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R-and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem, 12, 1559-67.
  61. Muti P, Quattrin T, Grant BJB, et al (2002). Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev, 11, 1361-8.
  62. Ogasawara M, Sirbasku DA (1988). A new serum-free method of measuring growth factor activities for human breast cancer cells in culture. In Vitro Cell Dev Biol, 24, 911-20.
  63. Oh SW, Park CY, Lee ES, et al (2011). Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res, 13, R34.
  64. Okamoto Y, Kihara S, Ouchi N, et al (2002). Adiponectin reduces atherosclerosis in adipoprotein E-deficient mice. Circulation, 106, 2767-70.
  65. Osborne CK, Monaco ME, Lippman ME, Kahn CR (1987). Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in longterm tissue culture. Cancer Res, 38, 94-102.
  66. Petridou E, Papadiamantis Y, Markopoulos C, et al (2004). Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control, 11, 383-8.
  67. Poretsky L, Kalin MF, (1987). The gonadotropic function of insulin. Endocr Rev, 8, 132-41.
  68. Pugeat M, Crave JC, Elmidani M, et al (1991). Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol, 40, 841-9.
  69. Rajala M, Scherer P (2003). The adipocyte-At the crossroads of homeostasis, inflammation, and atherosclerosis. Endocrinol, 144, 3765-73.
  70. Rose DP, Komninou D, Stephenson GD (2004). Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev, 5, 153-65.
  71. Rose DP, Vona-Davis L (2012). The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocrine-Related Cancer, 19, 225-41.
  72. Rufer CE, Kulling SE (2006). Angtioxidant activity of isoflavones and their major metabolites using different in vitro assays. J Agric Food Chem, 54, 2926-31.
  73. Ruhl CE, Everhart JE (2001). Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr, 74, 295-301.
  74. Scheen Al, Lefebvre PJ (1996). Insulin action in man. Diadete Metab, 22, 105-10.
  75. Sepp-Lorenzino L, Rosen N, Lebwohl DE (1994). Insulin and insulin-like growth factor signaling are defective in the MDA-MB-468 human breast cancer cell line. Cell Growth Differ, 5, 1077-83.
  76. Setchell KDR, Brown NM, Lydeking-Olsen E (2002). The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr, 132, 3577-84.
  77. Setchell KDR, Clerici C, Lephart E, et al (2005) S-equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr, 81, 1072-9.
  78. Setchell KDR, Cole SJ (2006). Method of defining equolproducer status and its frequency among vegetarians. J Nutr, 136, 2188-93.
  79. Shafie SM, Hilf R (1981). Insulin receptor levels and magnitude of insulin-induced responses in 7,12-dimethylbenz(a) anthracene-induced mammary tumors in rats. Cancer Res, 41, 826-9.
  80. Shafie SM, Grantham FH (1981). Role of hormones in the growth and regression of human breast cancer cell (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst, 67, 51-6.
  81. Steppan CM, Bailey ST, Bhat S, et al (2001). The hormone resistin links obesity to diabetes. Nature, 409, 307-12.
  82. Tian YF, Chu CH, Wu MH, et al (2007). Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocrine-Related Cancer, 14, 669-77.
  83. Trock BJ, Hilakivi-Clarke L, Clarke R (2006). Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst, 98, 459-71.
  84. Tworoger SS, Eliassen AH, Kelesidis T, et al (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab, 92, 1510-6.
  85. Verheus M, van Gils CH, Keinan-Boker L, et al (2007). Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol, 25, 648-55.
  86. Vona-Davis L, Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer, 14, 189-206.
  87. Vona-Davis L, Howard-McNatt M, Rose DP (2007). Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev, 8, 395-408.
  88. Wang Y, Lam JB, Lam KS, et al (2006). Adiponectin modulates the glycogen synthase kinase-3${\beta}$/${\beta}$-catenin signaling pathway and attenuates mammary tumorigenesis of MDAMB-231 cells in nude mice. Cancer Res, 66, 11462-70.
  89. Ward H, Chapelais G, Kuhnle GG, et al (2008). European Prospective into Cancer-Norfolk cohort. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res, 10, 32.
  90. Weyer C, Funahashi T, Tanaka S, et al (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 86, 1930-5.
  91. Whitelaw DC, Gilbey SG (1998). Insulin resistance. Ann Clin Biochem, 35, 567-83.
  92. Wu AH, Yu MC, Tseng CC, Twaddle NC, Doerge DR (2004). Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County. Carcinogenesis, 25, 77-81.
  93. Wu AH, Yu MC, Tseng CC, Pike MC (2008). Epidemiology of soy exposures and breast cancer risk. Br J Cancer, 98, 9-14.
  94. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 423, 762-9.
  95. Yang G, Lu G, Jin F, et al (2001). Population-based case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomark Prev, 10, 1207-11.
  96. Yokota T, Oritani K, Takahashi I, et al (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96, 1723-32.
  97. Zheng W, Dai Q, Custer LJ, et al (1999). Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomark Prev, 8, 35-40.

Cited by

  1. Review: Anti-Oxidant and Anti-Aging Properties of Equol in Prostate Health (BPH) vol.04, pp.01, 2014,
  2. Garcinol, an Acetyltransferase Inhibitor, Suppresses Proliferation of Breast Cancer Cell Line MCF-7 Promoted by 17β-Estradiol vol.15, pp.12, 2014,
  3. Insulin Promotes Proliferation and Migration of Breast Cancer Cells through the Extracellular Regulated Kinase Pathway vol.15, pp.15, 2014,
  4. Isoflavones: Chemistry, Analysis, Functions and Effects on Health and Cancer vol.15, pp.17, 2014,
  5. Body Mass Index Effects on Risk of Ovarian Cancer: A Meta-Analysis vol.15, pp.18, 2014,
  6. Overweight, Obesity, Oxidative Stress and the Risk of Breast Cancer vol.15, pp.22, 2014,
  7. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps vol.44, pp.8, 2014,
  8. Lifestyle Components and Primary Breast Cancer Prevention vol.15, pp.24, 2014,
  9. Passive Smoking and Breast Cancer - a Suspicious Link vol.16, pp.14, 2015,